Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
EMVision Medical Devices Prepares Study to Support Remote Use of emu Bedside Brain Scanner
EMVision moves to remote stroke care with emu bedside scanner; regional study protocol set, telehealth-enabled diagnosis could shift rural care (ASX: EMV).
Latest Stories — SECTOR DESK
Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test
Cleo Diagnostics begins analytical validation of eight-biomarker pre-surgical ovarian cancer blood test after receiving 125 kits, advancing FDA submission.
AdAlta Partner to Provide Adapted CAR-T Mesothelioma Therapy in China under Special Access Scheme
AdAlta's EW-001 CAR-T gains China access under Lecheng scheme; BZDS1901 approved for mesothelioma at Ruijin Hospital, boosting ASX:1AD upside.
Vitrafy Life Sciences Enters US Cell and Gene Therapy Space with Cryopreservation Agreement
Vitrafy Life Sciences nets first North American cell/gene therapy deployment with Charter Medical to install its cryopreservation ecosystem (six-month term).
Racura Oncology Opens Korean Recruitment for RC220 Phase 1 Solid Tumours Trial
Racura Oncology opens Korea recruitment for RC220 Phase 1 solid tumours trial, expanding to Ewha, Severance and Samsung Medical Center to accelerate enrolment.
Optiscan Launches US Study of InVue and InForm Imaging Devices for Head and Neck Cancer Surgeries
Optiscan kicks off US Mayo Clinic study of 35-patient InVue/InForm for head and neck cancer; real-time intraoperative imaging aims to back FDA submissions.
Avecho Biotechnology Restarts Final Recruitment Stage for Key Insomnia Trial
Avecho restarts final recruitment for Phase III insomnia trial; 320 more participants to reach 519 after positive interim DMB, de-risked with ~12-month plan.
Austco Healthcare Posts Record FY26 Revenue as Recurring Income Builds
Austco Healthcare posts record FY26 revenue of $94.2m as recurring SMA income grows; strong order book and cash build, flagging upbeat FY27 prospects.
Prescient Therapeutics’ First-in-Class Cancer Drug Approaching a Pivotal Moment
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b potential big-pharma partner as first-in-class GGT-1/RAS hit.
Biome Australia Enters Probiotics Market in China with Exclusive H&S Global Deal
Biome Australia secures exclusive China CBEC deal with H&S Global for Activated Probiotics; aims for FY27 launch in US$10.8B market.
Preclinical Data Shows Noxopharm’s Sofra Technology Can Enhance Current Cancer Treatments
Noxopharm's Sofra preclinical data show immune activation with dying cancer cells, hinting Sofra can boost standard cancer therapies.
Integral Diagnostics Lifts FY26 Earnings as Capitol Synergies Beat Expectations
Integral Diagnostics FY26 revenue up 25.6% to A$788.7m; NPAT up 50% to A$47.4m as Capitol synergies beat; final dividend 6.0c; margins lift.